Global prenatal DNA sequencing market expected to generate around USD 2,605 million by 2025, growing at a CAGR of around 13.37% between 2019 and 2025. DNA sequencing is defined as a process that is used to determine the order or sequence of nucleotides within DNA particles.
The report covers a forecast and an analysis of the prenatal DNA sequencing market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints of the prenatal DNA sequencing market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the prenatal DNA sequencing market on a global and regional level.
In order to give the users of this report a comprehensive view of the prenatal DNA sequencing market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis to give a broader overview of the key players in the prenatal DNA sequencing market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.
The study provides a decisive view of the prenatal DNA sequencing market by segmenting it based on application and region. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Some major players in the prenatal DNA sequencing market are Agilent Technologies, F. Hoffmann-La Roche, Laboratory Corporation of America, Natera, Genomic Health, Myriad Genetics, Invitae, BGI, and Illumina.
This report segments the global prenatal DNA sequencing market into:
Global Prenatal DNA Sequencing Market: By Application
Global Prenatal DNA Sequencing Market: By Region
DNA sequencing is defined as a process that is used to determine the order or sequence of nucleotides within DNA particles. Prenatal DNA sequencing is a DNA sequencing method extracted from an expectant women’s blood to disclose the full genetic code of a fetus. It is used to structure the whole genome of an unborn baby, which helps in effectively detecting the diseases cystic fibrosis, down syndrome, cancer, etc. The prenatal DNA sequencing technology has huge acceptance across the globe, due to its various applications. This technology has a huge impact on the public healthcare sector. Various companies and laboratories have introduced diagnostic tests based on sequencing technology. The demand for Prenatal DNA sequencing technology is increasing worldwide, due to its wide and effective use. Despite its wide application and usage, the DNA sequencing instruments are facing challenges in terms of high cost as many small laboratories can’t afford the prenatal DNA sequencing instruments.
There are various factors driving the prenatal DNA sequencing market globally. The demand for prenatal DNA sequencing technology is increasing rapidly in the global market, due to the introduction of new technologies of DNA sequencing process and increasing incidences of chronic diseases like cancer and AIDS, among others. In addition, increasing R&D investments for preventing chronic diseases also contribute to the prenatal DNA sequencing market globally. However, the high cost of DNA sequencing may be a major restraining factor affecting the prenatal DNA sequencing market development in the years ahead. Nevertheless, the increasing number of laboratories and various diagnostic firms provide ample opportunity for the prenatal DNA sequencing market growth.
The prenatal DNA sequencing market is segmented on the basis of application and region. The application segment is divided into down syndrome, hemophilia, cystic fibrosis, AIDS, DiGeorge syndrome, autism, cancer, and others. Genetic diseases, such as AIDS, hemophilia, and down syndrome, holds the largest market share and are expected to dominate the prenatal DNA sequencing market in terms of revenue in the years ahead, owing to the increasing cases of AIDS, cancer, and other chronic diseases.
North America dominates the market due to the rising number of genetic diseases that require an increased number of hospitals for treatment. The U.S is the main market players, due to the availability of advanced healthcare infrastructure, technological improvements in DNA sequencing, and growing R&D investment in prenatal DNA sequencing technology. Europe held the second spot of the prenatal DNA sequencing market share in 2018. The Asia Pacific prenatal DNA sequencing market is the fastest-growing region that shall register the highest CAGR over the forecast time period. The key factors driving this regional market are growing population base, rising number of patients suffering from cancer, AIDS, etc., and increasing healthcare expenditure. The Middle East and Africa prenatal DNA sequencing market will show sluggish growth in the future, owing to the lack of funding required for the implementation of prenatal DNA sequencing technique due to the high installation costs.
Some major players in the prenatal DNA sequencing market are Agilent Technologies, F. Hoffmann-La Roche, Laboratory Corporation of America, Natera, Genomic Health, Myriad Genetics, Invitae, BGI, and Illumina
Request the coronavirus impact analysis across industries and markets